IDEAYA Biosciences, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from IDEAYA Biosciences, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Debt Due Cover Ratio: Operating cash was negative last year, while some debt falls due within a year. Lower than 92% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-50.5×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 72% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
1/3 · 1/3Sales grew in 1 of the last 3 years; profit grew in 1 of 3.
Less steady than 70% of Healthcare companies in United States.
Growth Efficiency Ratio
−$33Sales grew 329% in 3 years, but profit fell: $33 less profit per $100 of extra sales.
Lower than 79% of Healthcare companies in United States.
Asset Productivity Ratio
+329% / +186%In 3 years sales changed by +329% while total assets changed by +186%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
-209.7×Operating cash was negative last year, while some debt falls due within a year.
Lower than 92% of Healthcare companies in United States.
Cash Cushion Ratio
+18%Cash, after subtracting all debt, equals 18% of its market value (net cash).
Higher than 60% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
IDEAYA Biosciences, Inc. made a loss over the last year. IDEAYA Biosciences, Inc. owes $0.08 for every $1 it owns. IDEAYA Biosciences, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossIDEAYA Biosciences, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
2.79The share price is 2.79 times IDEAYA Biosciences, Inc.'s book value per share, higher than 53% of Healthcare companies in United States.
Market cap
$3.3 BThe total market value of all of IDEAYA Biosciences, Inc.'s shares at today's price (share price × number of shares), larger than 81% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
$1.2 BWhat IDEAYA Biosciences, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$12.43Net worth divided by the number of shares. The share price of $34.71 is 2.8 times this, which is the P/B above.
Return on equity (ROE)
-16.2%IDEAYA Biosciences, Inc. lost 16.2% of its shareholders' money over the last year, higher than 67% of Healthcare companies in United States.
Owes vs Owns
0.08×IDEAYA Biosciences, Inc. owes $0.08 for every $1 it owns (low), lower than 89% of Healthcare companies in United States.
Dividend yield
NoneIDEAYA Biosciences, Inc. does not currently pay a dividend.
Revenue growth
+3024%Revenue rose 3024% in the year to Dec 2025, and grew 63% a year on average over 3 years.
Profit growth
LossIDEAYA Biosciences, Inc. made a loss in each of the last two years.
Profit margin
-52.0%IDEAYA Biosciences, Inc. lost $52 for every $100 of revenue.
Cash vs debt
Net cashIDEAYA Biosciences, Inc. held $611 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For IDEAYA Biosciences, Inc.: $3.3 B ÷ $1.2 B (30 Jun 2026) = 2.8.
What is IDEAYA Biosciences, Inc.'s return on equity?
IDEAYA Biosciences, Inc. lost 16.2% of its shareholders' money over the last year, higher than 67% of Healthcare companies in United States.
How much does IDEAYA Biosciences, Inc. owe compared with what it owns?
IDEAYA Biosciences, Inc. owes $0.08 for every $1 it owns (low), lower than 89% of Healthcare companies in United States.
Does IDEAYA Biosciences, Inc. pay a dividend?
No. IDEAYA Biosciences, Inc. does not currently pay a dividend.
Is IDEAYA Biosciences, Inc.'s revenue growing?
Revenue rose 3024% in the year to Dec 2025, and grew 63% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.